Результати пошуку - Ming‐Shyang Huang

  • Показ 1 - 3 результатів із 3
Уточнити результати
  1. 1
    Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells

    Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells за авторством An-Fu Lee, Man‐Chin Chen, Chao‐Ju Chen, Chih‐Jen Yang, Ming‐Shyang Huang, Yu‐Peng Liu

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  2. 2
    <scp>PCAF</scp>‐mediated acetylation of <scp>ISX</scp> recruits <scp>BRD</scp>4 to promote epithelial‐mesenchymal transition

    <scp>PCAF</scp>‐mediated acetylation of <scp>ISX</scp> recruits <scp>BRD</scp>4 to promote epithelial‐mesenchymal transition за авторством Li‐Ting Wang, Kwei‐Yan Liu, W.Y. Jeng, Cheng‐Ming Chiang, Chee‐Yin Chai, Shyh‐Shin Chiou, Ming‐Shyang Huang, Kazunari K. Yokoyama, Shen‐Nien Wang, Shau‐Ku Huang, Shih‐Hsien Hsu

    Опубліковано 2020
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]

    Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients... за авторством Shih-Lung Cheng, Ming-Lin Ho, Yun-Fa Lai, Hao‐Chien Wang, Jeng‐Yuan Hsu, Shih‐Feng Liu, Ming-Shyang Huang, Cheng-Hung Lee, Ching‐Hsiung Lin, Liang‐Wen Hang, Yu‐Chih Liu, Kuang‐Yao Yang, Jia-Horng Wang

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Errata/Corrigenda
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: